A Phase III trial of GlaxoSmithKline's vaccine against the virus that causes cervical cancer showed the immune response was twice as strong for girls aged 10 to 14 than for females 15 to 25, suggesting early vaccination achieves the most prolonged protection. A GSK researcher said the concentration of antibodies to the virus were twice as high in the bloodstreams of young girls compared with older subjects.

Full Story:

Related Summaries